Several anti-angiogenic agents have been tested in advanced gastric cancer treatment, but so far, only ramucirumab has proved its value in association with single-agent chemotherapy, and it is the only anti-VEGF agent approved in this setting [81,82]. This evidence concerns the gene VEGFA and gastric cancer.